About
Addiction Therapies
Areas of Focus
Categories
Small Molecule PharmaceuticalBiotech
Team (8)
Adrienne MacMillan
Adrienne MacMillan
Amygdala Neurosciences
team_member
Brent Blackburn
Brent Blackburn, PhD
Amygdala Neurosciences
team_member
Howard Jaffe
Howard Jaffe, MD
Amygdala Neurosciences
team_member
Ivan Diamond
Ivan Diamond, MD, PhD
Amygdala Neurosciences
team_member
Lou Lange
Lou Lange, MD, PhD
Amygdala Neurosciences
team_member
Mack Mitchell
Mack Mitchell, MD
Amygdala Neurosciences
team_member
Clinical Trials (2)
View allTotal Trials
2
As Lead Sponsor
1
As Collaborator
1
Total Enrollment
48
By Phase
PHASE2: 1PHASE1: 1
By Status
WITHDRAWN: 1COMPLETED: 1
Clinical Trials Pipeline2 trials
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Phase 1/2
Phase 2/3
N/A
2016
2017
2018
2019
2020
2021
2022
2023
Today
Hover over trial bars to see details
Recent Trials
NCT04311294Collaborator
Development of a Selective ALDH2 Inhibitor to Treat AUD
PHASE2Withdrawn
Started: Apr 30, 2020 · Completed: Mar 31, 2022
NCT03203499Lead Sponsor
A Study to Evaluate the Safety of the Coadministration of ANS-6637 and Ethanol
PHASE1Completed
48 participants
Started: Feb 27, 2017 · Completed: Nov 15, 2017
Locations (1)
Headquarters
Los Altos, CA, United States
Map
Loading map...